Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib

被引:0
作者
Hongming Pan
Zhanggui Wang
Liming Jiang
Xinbing Sui
Liangkun You
Jiawei Shou
Zhao Jing
Jiansheng Xie
Weiting Ge
Xiujun Cai
Wendong Huang
Weidong Han
机构
[1] Sir Run Run Shaw Hospital,Department of Medical Oncology
[2] College of Medicine,Department of General Surgery
[3] Zhejiang University,Division of Molecular Diabetes Research, Department of Diabetes and Metabolic Diseases Research
[4] Laboratory of Cancer Biology,undefined
[5] Cancer Institute,undefined
[6] The Second Affiliated Hospital,undefined
[7] College of Medicine,undefined
[8] Zhejiang University,undefined
[9] Sir Run Run Shaw Hospital,undefined
[10] College of Medicine,undefined
[11] Zhejiang University,undefined
[12] Beckman Research Institute,undefined
[13] City of Hope National Medical Center,undefined
[14] Institute of Clinical Science,undefined
[15] Sir Run Run Shaw Hospital,undefined
[16] College of Medicine,undefined
[17] Zhejiang University,undefined
来源
Scientific Reports | / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Autophagy is a critical survival pathway for cancer cells under conditions of stress. Thus, induction of autophagy has emerged as a drug resistance mechanism. This study is to determine whether autophagy is activated by a novel multikinase inhibitor linifanib, thereby impairing the sensitivity of hepatocellular carcinoma (HCC) cells to this targeted therapy. Here, we found that linifanib induced a high level of autophagy in HCC cells, which was accompanied by suppression of phosphorylation of PDGFR-β and its downstream Akt/mTOR and Mek/Erk signaling pathways. Cell death induced by linifanib was greatly enhanced after autophagy inhibition by the pharmacological inhibitors or siRNAs against autophagy related genes, ATG5 and ATG7, in vitro. Moreover, HCQ, an FDA-approved drug used to inhibit autophagy, could significantly augment the anti-HCC effect of linifanib in a mouse xenograft model. In conclusion, linifanib can induce cytoprotective autophagy by suppression of PDGFR-β activities in HCC cells. Thus, autophagy inhibition represents a promising approach to improve the efficacy of linifanib in the treatment of HCC patients.
引用
收藏
相关论文
共 72 条
[1]  
Raza A(2014)Hepatocellular carcinoma review: Current treatment and evidence-based medicine World journal of gastroenterology : WJG 20 4115-4127
[2]  
Sood GK(2009)A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma Cancer Chemother Pharmacol 63 929-935
[3]  
Uhm JE(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[4]  
Llovet JM(2006)Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor Mol Cancer Ther 5 995-1006
[5]  
Albert DH(2014)PDGF receptor signaling networks in normal and cancer cells Cytokine & growth factor reviews 25 273-283
[6]  
Demoulin JB(2006)Biology of platelet-derived growth factor and its involvement in disease Mayo Clin Proc 81 1241-1257
[7]  
Essaghir A(1999)Mechanism of action and in vivo role of platelet-derived growth factor Physiol Rev 79 1283-1316
[8]  
Alvarez RH(2010)ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways Mol Cancer Ther 9 653-660
[9]  
Kantarjian HM(2008)Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway Leukemia 22 138-146
[10]  
Cortes JE(2013)Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma Cancer 119 380-387